Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma

BMC Cancer

Table 1 Association between expression level of GPR155 mRNA and clinicopathological parameters in 144 patients with hepatocellular carcinoma

Clinicopathological parameters	Downregulation of GPR155 (n = 57)	Others (n = 87)	p value
Age			0.349
< 65 year	23	42
≥ 65 year	34	45
Gender			0.013*
Female	4	19
Male	53	68
Background liver			0.188
Normal liver	2	8
Chronic hepatitis	37	45
Cirrhosis	18	34
Pugh-Child’s classification			0.044*
A	50	84
B	7	3
Hepatitis virus			0.757
Absent	9	18
HBV	15	22
HCV	33	47
AFP (ng/ml)			0.002*
≤ 20	22	56
> 20	35	31
PIVKA II (mAU/ml)			0.002*
≤ 40	14	44
> 40	43	43
Tumor multiplicity			0.078
Solitary	40	72
Multiple	17	15
Tumor size			0.120
< 3.0 cm	14	32
≥ 3.0 cm	43	55
Differentiation			0.009*
Well	7	28
Moderate	43	55
Poor	7	4
Growth type			0.495
Expansive growth	46	74
Invasive growth	11	13
Serosal infiltration			0.031*
Absent	49	60
Present	23	12
Formation of capsule			<0.001*
Absent	33	76
Present	24	11
Infiltration to capsule			0.035*
Absent	20	46
Present	37	41
Septum formation			0.036*
Absent	14	36
Present	43	51
Vascular invasion			<0.001*
Absent	34	74
Present	23	13
UICC pathological stage			<0.001*
I	25	65
II	22	15
III	10	7

Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, AFP α-fetoprotein, PIVKA protein induced by vitamin K antagonists, UICC Union for International Cancer Control. *Statistically significant difference (p < 0.05)

ISSN: 1471-2407